Ultragenyx Pharmaceutical RARE Non Cash Royalty Revenue
Non Cash Royalty Revenue at other companies
Other financials
Where this comes from
Reported directly by Ultragenyx Pharmaceutical in its filing.
Tagged under the XBRL concept rare:NonCashRoyaltyRevenue.
The official record: Ultragenyx Pharmaceutical’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ultragenyx Pharmaceutical's non cash royalty revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ultragenyx Pharmaceutical's non cash royalty revenue?
- Ultragenyx Pharmaceutical (RARE) reported non cash royalty revenue of $20M in Q1 2026.
- How has Ultragenyx Pharmaceutical's non cash royalty revenue changed year-over-year?
- Ultragenyx Pharmaceutical's non cash royalty revenue increased by 5.3% year-over-year, from $19M to $20M.
- What is the long-term trend for Ultragenyx Pharmaceutical's non cash royalty revenue?
- Over 2 years (2023 to 2025), Ultragenyx Pharmaceutical's non cash royalty revenue has grown at a 27.4% compound annual growth rate (CAGR), from $69M to $112M.
- What does non cash royalty revenue mean?
- This represents revenue recognized from royalty agreements that does not involve an immediate cash receipt during the period. It typically arises from accounting standards requiring revenue recognition before the actual cash settlement occurs. Monitoring this helps investors distinguish between reported revenue growth and actual cash generation from intellectual property.